Kathryn Weston Clerici

Kathryn Weston Clerici
+1 (617) 5701363

Kathryn Clerici is an associate in the firm’s Business Law Department. She joined Goodwin in 2019.


Ms. Clerici’s recent client representations include the following:

  • BeiGene in its $2.08 billion registered direct offering
  • Forma Therapeutics in connection with:
    • its $100 million Series D financing
    • its $319.3 million initial public offering
    • its $275.8 million follow-on offering
  • Cullinan Oncology in its $287.4 million initial public offering
  • Avadel Pharmaceuticals in connection with:
    • its $125 million follow-on offering
    • its $50 million at-the-market sales transaction
    • its $65 million private placement
  • bluebird bio in its $575 million follow-on offering
  • argenx in its $557 million follow-on offering
  • The underwriters in IBEX’s $90.5 million initial public offering
  • The underwriters in Pandion Therapeutics’ $135 million initial public offering
  • resTORbio in its reverse merger with Adicet Bio

Professional Activities

Ms. Clerici is a member of the Boston Bar Association.

Professional Experience

While attending law school, Ms. Clerici worked as a corporate summer associate at Goodwin and a litigation summer associate at LibbyHoopes, P.C. in Boston. She was also an executive senior editor and a staff writer for the Boston College Law Review.




Boston College Law School

(magna cum laude, Order of the Coif)


Boston College



  • Massachusetts